abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis India drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Novartis India pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Novartis India drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Novartis India's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
aliskiren
Cardiovascular system (C09)Cardiovascular system (C09) compound in Novartis India's portfolio. Mechanism: Renin inhibitor.
- Mechanism
- Renin inhibitor
-
alpelisib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- Mechanism
- PI3-kinase p110-alpha subunit inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Glutamate [NMDA] receptor antagonist.
- Mechanism
- Glutamate [NMDA] receptor antagonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Novartis India's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Novartis India in public FDA and regional records.
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
arginine
Various (V03)Various (V03) compound in Novartis India's portfolio.
-
Development asset linked to Novartis India in public FDA and regional records.
-
asciminib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
- Target
- Tyrosine-protein kinase ABL1
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
belimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 13B.
- Target
- Tumor necrosis factor ligand superfamily member 13B
- Mechanism
- Tumor necrosis factor ligand superfamily member 13B inhibitor
-
bempedoic acid
Cardiovascular system (C10)US regulatory status: approved. Molecular target: ATP-citrate synthase.
- Target
- ATP-citrate synthase
- Mechanism
- ATP-citrate synthase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
bosutinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
- Target
- Tyrosine-protein kinase ABL1
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
brimonidine
Dermatologicals (D11)Dermatologicals (D11) compound in Novartis India's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
brinzolamide
Sensory organs (S01)US regulatory status: approved. Molecular target: Carbonic anhydrase 2.
- Target
- Carbonic anhydrase 2
- Mechanism
- Carbonic anhydrase II inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
brolucizumab
Sensory organs (S01)Sensory organs (S01) compound in Novartis India's portfolio. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
cabazitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
canakinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 beta.
- Target
- Interleukin-1 beta
- Mechanism
- Interleukin-1 beta inhibitor
-
Development asset linked to Novartis India in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
capmatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
carmustine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Glutathione reductase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
ceritinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- EML4-ALK
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in Novartis India's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Novartis India's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: Opioid receptors; mu/kappa/delta agonist.
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
Development asset linked to Novartis India in public FDA and regional records. Molecular target: Bile acids.
- Target
- Bile acids
- Mechanism
- Bile acids sequestering agent
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
dabrafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.
- Target
- Serine/threonine-protein kinase B-raf
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Progesterone receptor agonist
-
darolutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
deferasirox
Various (V03)US regulatory status: approved. Molecular target: Iron.
- Target
- Iron
- Mechanism
- Iron chelating agent
-
degarelix
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Novartis India's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Novartis India's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
dimethyl fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Novartis India's portfolio.
-
diroximel fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to Novartis India in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Progesterone receptor agonist
-
eltrombopag
Blood and blood forming organs (B02)US regulatory status: approved. Mechanism: Thrombopoietin receptor agonist.
- Mechanism
- Thrombopoietin receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
entacapone
Nervous system (N04)US regulatory status: approved. Molecular target: Catechol O-methyltransferase.
- Target
- Catechol O-methyltransferase
- Mechanism
- Catechol O-methyltransferase inhibitor
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: Type-1 angiotensin II receptor antagonist.
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.
- Target
- NPC1-like intracellular cholesterol transporter 1
- Mechanism
- Niemann-Pick C1-like protein 1 inhibitor
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor.
- Target
- Sphingosine 1-phosphate receptor
- Mechanism
- Sphingosine 1-phosphate receptor agonist
-
florbetaben (18f)
Various (V09)Various (V09) compound in Novartis India's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
gefitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
glycopyrronium
Respiratory system (R03)Respiratory system (R03) compound in Novartis India's portfolio. Mechanism: Muscarinic acetylcholine receptor inhibitor.
- Mechanism
- Muscarinic acetylcholine receptor inhibitor
-
glycopyrronium bromide
Respiratory system (R03)Respiratory system (R03) compound in Novartis India's portfolio. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
gozetotide
Various (V09)Various (V09) compound in Novartis India's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records. Molecular target: Tumor necrosis factor receptor superfamily member 13C.
- Target
- Tumor necrosis factor receptor superfamily member 13C
- Mechanism
- Tumor necrosis factor receptor superfamily member 13C binding agent
-
ibrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
inclisiran
Cardiovascular system (C10)Cardiovascular system (C10) compound in Novartis India's portfolio. Molecular target: PCSK9 mRNA.
- Target
- PCSK9 mRNA
- Mechanism
- PCSK9 mRNA RNAi inhibitor
-
US regulatory status: approved. Molecular target: PCSK9 mRNA.
- Target
- PCSK9 mRNA
- Mechanism
- PCSK9 mRNA rnai inhibitor
-
indacaterol
Respiratory system (R03)Respiratory system (R03) compound in Novartis India's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Novartis India's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Novartis India's portfolio.
-
influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Novartis India's portfolio.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
insulin lispro
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
interferon alfa-2b
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
interferon beta-1b
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
iptacopan
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Novartis India's portfolio. Molecular target: Complement factor B.
- Target
- Complement factor B
- Mechanism
- Complement factor B inhibitor
-
US regulatory status: approved. Molecular target: Complement factor B.
- Target
- Complement factor B
- Mechanism
- Complement factor B inhibitor
-
irbesartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Novartis India in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
lapatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Novartis India's portfolio. Mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor.
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
lutetium (177lu) oxodotreotide
Various (V10)Various (V10) compound in Novartis India's portfolio. Molecular target: Somatostatin receptor.
- Target
- Somatostatin receptor
- Mechanism
- Somatostatin receptor binding agent
-
lutetium (177lu) vipivotide tetraxetan
Various (V10)Various (V10) compound in Novartis India's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA disrupting agent
-
Development asset linked to Novartis India in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Novartis India in public FDA and regional records.
-
Development asset linked to Novartis India in public FDA and regional records.
-
melphalan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor